HK biopharma sector surges on innovative drug policy boost, attracting capital
On July 28, 2026, the Hong Kong stock market saw a strong rally in the biopharmaceutical sector. The Hang Seng Healthcare Index surged 4.2% intraday, leading the Hang Seng composite industry indices. By close, multiple innovative drug-related stocks rose over 10%, with BeiGene (06160.HK) up 12.5%, Innovent Biologics (01801.HK) up 11.3%, and Akeso (09926.HK) up 9.8%. Market capital clearly concentrated in the pharmaceutical sector, indicating increased investor confidence in the innovative drug track.
Policy package acts as catalyst
The direct catalyst for this pharmaceutical rally came from two aspects. First, on July 27, the National Medical Products Administration issued the "Implementing Rules for Accelerated Approval and Conditional Approval of Innovative Drugs (2026 Revision)", which clarified that breakthrough therapies and rare disease drugs will be included in priority review channels, reducing approval timelines by over 30%. This policy was interpreted by the market as a major positive for innovative drug R&D companies, especially biotechnology companies listed in Hong Kong, whose core products could be approved faster. Second, the Guangdong-Hong Kong-Macao Greater Bay Area cross-border medical cooperation pilot plan was officially announced on July 28, allowing Hong Kong and Macao medical institutions to set up wholly-owned hospitals in mainland cities within the GBA and directly introduce new drugs and medical devices already listed in Hong Kong. This opens a fast track for Hong Kong-listed innovative drug companies to enter the mainland market.
Capital flow in HK pharma sector
In terms of capital flow, southbound capital net bought approximately HK$4.5 billion in the pharmaceutical sector through Stock Connect today, accounting for 62% of the day's total southbound net buying. Among them, BeiGene, Innovent Biologics, and Akeso ranked top three in net buying. On the foreign side, institutions such as Morgan Stanley and Goldman Sachs significantly increased positions early in the session, primarily based on policy dividends and valuation repair. In fact, the Hong Kong pharma sector had corrected significantly since its 2025 peak, with the average P/E ratio of Hang Seng Healthcare Index components falling to 22 times, a three-year low. After the policy announcement, some institutions believe that the innovative drug sector has entered a medium- to long-term window for allocation.
Analysis of leading stocks
BeiGene's core product zanubrutinib has been approved in the US and Europe, and under the new rules, its domestic indications are expected to expand rapidly, driving revenue growth. Innovent Biologics benefits from the expectation of new indications for its PD-1 inhibitor sintilimab and the impressive clinical data of its bispecific antibody in collaboration with Incyte. Akeso's bispecific antibody AK104 shows superior efficacy in cervical cancer treatment compared to existing therapies, leading the market to give it a higher valuation for its commercialization prospects. Notably, these companies are all listed under HKEX Chapter 18A (pre-revenue biotech companies), and the policy dividend directly eases their cash flow pressure and shortens the path to profitability.
Hang Seng Index performance and sector linkage
Driven by the pharmaceutical sector, the Hang Seng Index opened lower but moved higher today, closing at 18,726 points, up 0.3%. However, technology and financial stocks showed divergence, with heavyweight stocks such as Tencent and Alibaba performing flat. Market analysts pointed out that the strength of the pharmaceutical sector did not fully activate the broader market, indicating that capital is more structural rotation. The Hang Seng Index is currently still below the 19,000-point level, and short-term attention needs to be paid to the Fed's interest rate decision and mainland economic data. However, the independent rally of the pharmaceutical sector provides clear trading opportunities for investors.
Institutional views and outlook
Multiple institutions published research reports today bullish on the Hong Kong pharma sector. CICC believes that the innovative drug policy system is becoming more complete, and Chinese pharmaceutical innovation is moving from following to leading, with Hong Kong as the main listing venue for innovative drug companies, continuously benefiting. Goldman Sachs pointed out that current sector valuation has a safety margin, suggesting investors focus on companies with global clinical capabilities. Some analysts also caution that short-term sentiment may lead to profit-taking after overheating, but the medium-to-long-term trend is positive. Overall, driven by policy dividends, the Hong Kong biopharmaceutical sector is expected to usher in a new round of rally, and today's surge may just be the beginning.
Risk warning
The stocks mentioned in this article are only analysis cases and do not constitute investment advice. The stock market carries risks; investment should be cautious. Investors should pay attention to risks such as policy implementation falling short of expectations, R&D failure, and intensified market competition.